FindTrial
Sign In

A Prognostic Study on Dexmedetomidine in the Treatment of Insomnia Patients and the Establishment of an Individualized Prediction Model

A Prognostic Study on Dexmedetomidine in the Treatment of Insomnia Patients and the Establishment of an Individualized Prediction Model

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600120177
Enrollment
Unknown
Registered
2026-03-10
Start date
2026-03-10
Completion date
Unknown
Last updated
2026-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Insomnia

Interventions

The dexmedetomidine group:N/A

Sponsors

Changzhou No. 2 People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age range: 18 - 75 years old; 2. Meets the diagnostic criteria of ICSD-3; 3. Baseline ISI score = 15 points; 4. Duration of illness = 3 months.

Exclusion criteria

Exclusion criteria: 1. Severe OSA (AHI > 15); 2. Severe liver and kidney dysfunction; 3. Symptomatic bradycardia or hypotension; 4. Pregnant or lactating; 5. Missing critical data.

Design outcomes

Primary

MeasureTime frame
Insomnia Severity Index;—

Secondary

MeasureTime frame
Pittsburgh Sleep Quality Index ;—

Countries

China

Contacts

Public ContactWu Zhouquan

Changzhou No. 2 People's Hospital

wuzhouquan2005@126.com+86 138 6102 3270

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 20, 2026